- Home
- CRVS vs FUND Comparison
CRVS vs FUND Comparison
Compare CRVS & FUND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- FUND
- Stock Information
- Founded
- CRVS 2014
- FUND 1988
- Country
- CRVS United States
- FUND Canada
- Employees
- CRVS N/A
- FUND N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- FUND Investment Managers
- Sector
- CRVS Health Care
- FUND Finance
- Exchange
- CRVS Nasdaq
- FUND Nasdaq
- Market Cap
- CRVS 257.0M
- FUND 228.2M
- IPO Year
- CRVS 2016
- FUND N/A
- Fundamental
- Price
- CRVS $2.99
- FUND $7.11
- Analyst Decision
- CRVS Strong Buy
- FUND
- Analyst Count
- CRVS 5
- FUND 0
- Target Price
- CRVS $12.63
- FUND N/A
- AVG Volume (30 Days)
- CRVS 715.8K
- FUND 32.5K
- Earning Date
- CRVS 05-05-2025
- FUND 01-01-0001
- Dividend Yield
- CRVS N/A
- FUND 6.64%
- EPS Growth
- CRVS N/A
- FUND N/A
- EPS
- CRVS N/A
- FUND 0.93
- Revenue
- CRVS N/A
- FUND N/A
- Revenue This Year
- CRVS N/A
- FUND N/A
- Revenue Next Year
- CRVS N/A
- FUND N/A
- P/E Ratio
- CRVS N/A
- FUND $8.33
- Revenue Growth
- CRVS N/A
- FUND N/A
- 52 Week Low
- CRVS $1.30
- FUND $6.75
- 52 Week High
- CRVS $10.00
- FUND $8.47
- Technical
- Relative Strength Index (RSI)
- CRVS 26.38
- FUND 34.73
- Support Level
- CRVS $3.06
- FUND $7.31
- Resistance Level
- CRVS $3.31
- FUND $7.45
- Average True Range (ATR)
- CRVS 0.36
- FUND 0.09
- MACD
- CRVS -0.10
- FUND -0.00
- Stochastic Oscillator
- CRVS 1.11
- FUND 2.86
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About FUND Sprott Focus Trust Inc.
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.